Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 9/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | CCR2 | P41597 | 2/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | PTPRB | P23467 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27583385 | 0.93 | SIRT1 (0.44) | SIRT1AOC3MAOBCCR2PI4KB | |
| SCHEMBL27583324 | 0.92 | AOC3 (0.40) | SIRT1AOC3MAOBSMN1; SMN2 | |
| SCHEMBL27583340 | 0.88 | AOC3 (0.36) | SIRT1AOC3MAOBHDAC1HDAC6 | |
| SCHEMBL6499711 | 0.87 | SIRT1 (0.42) | SIRT1AOC3MAOBCCR2PI4KB | |
| SCHEMBL6489918 | 0.87 | ALDH1A1 (0.43) | SIRT1HDAC1HDAC6 | |
| SCHEMBL6498275 | 0.84 | MAPT (0.38) | HDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL6489886 | 0.81 | NR3C2 (0.39) | CCR2HDAC1HDAC6HDAC8 | |
| SCHEMBL27583338 | 0.80 | GSTO1 (0.35) | HDAC1HDAC6 | |
| SCHEMBL6492581 | 0.79 | SMN1; SMN2 (0.46) | SIRT1AOC3MAOBPI4KBSMN1; SMN2 | |
| SCHEMBL6495932 | 0.79 | AOC3 (0.54) | SIRT1AOC3MAOBCCR2PI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| CN-1478077-A | Benzamide compounds as APO B secretion inhibitors | ����ҩƷ��ҵ��ʽ���� | 2004-02-25 | — | — | CN | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | SIRT1 1218/4885AOC3 274/4885MAOB 10/4885 |
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | SIRT1 1393/4885AOC3 494/4885MAOB 284/4885 |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SIRT1 804/4885AOC3 227/4885MAOB 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.